The Asia Pacific Penicillin Drug Market should witness market growth of 4.2% CAGR during the forecast period (2023-2030).
A widely used drug for managing and treating different infections is penicillin. It is an ingredient of the class of medications known as beta-lactam antibiotics, including amoxicillin, ampicillin, and other antibiotics. When susceptible organisms cause bacterial infections, penicillin is often used as a therapy. Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus, and other gram-negative bacteria like Neisseria meningitidis are merely some of the microorganisms it is effective against.
Penicillin is offered in various dosage forms, including tablets, capsules, solutions, and injections, to accommodate various administration methods and patient requirements. Different dose forms may be used depending on the type of penicillin and the nation's healthcare system. Penicillin prevents the enzymes necessary for the cross-linking of peptidoglycan, a crucial component of the bacterial cell wall, thereby preventing the formation of bacterial cell walls. By weakening the cell wall, this inhibition causes the bacteria to lyse, which ultimately kills bacteria.
The National Library of Medicine reports that from 12.94 DID in 2018 to 14.45 DID in 2019, China's total antibiotic use across all healthcare settings has increased significantly. The consumption of antibiotics in PHCs exceeded 50%, notably in the central regions (59%-68%). According to the Annual Pharmaceutical Production Statistics Report from the Ministry of Health, Labour, and Welfare ("MHLW") of Japan, the Japanese industry for both over the counter and prescription reached a value of US$109 billion in 2020. The market is predicted to expand in this region due to rising antibiotic usage and advancements in the pharmaceutical sector.
The China market dominated the Asia Pacific Penicillin Drug Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1.1 billion by 2030. The Japan market is anticipated to grow at a CAGR of 3.5% during (2023-2030). Additionally, The India market would register a CAGR of 4.8% during (2023-2030).
Based on Source, the market is segmented into Semisynthetic Penicillin and Natural Penicillin. Based on Spectrum of Activity, the market is segmented into Broad spectrum, Extended spectrum and Narrow spectrum. Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on Route of Administration, the market is segmented into Parenteral and Oral. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Pfizer, Inc., Novartis AG, Lupin Limited, Abbott Laboratories, Cipla Limited, Takeda Pharmaceutical Company Limited, Alkem Laboratories Ltd., Teva Pharmaceuticals Industries Ltd., Sun Pharmaceutical Industries Ltd.
A widely used drug for managing and treating different infections is penicillin. It is an ingredient of the class of medications known as beta-lactam antibiotics, including amoxicillin, ampicillin, and other antibiotics. When susceptible organisms cause bacterial infections, penicillin is often used as a therapy. Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus, and other gram-negative bacteria like Neisseria meningitidis are merely some of the microorganisms it is effective against.
Penicillin is offered in various dosage forms, including tablets, capsules, solutions, and injections, to accommodate various administration methods and patient requirements. Different dose forms may be used depending on the type of penicillin and the nation's healthcare system. Penicillin prevents the enzymes necessary for the cross-linking of peptidoglycan, a crucial component of the bacterial cell wall, thereby preventing the formation of bacterial cell walls. By weakening the cell wall, this inhibition causes the bacteria to lyse, which ultimately kills bacteria.
The National Library of Medicine reports that from 12.94 DID in 2018 to 14.45 DID in 2019, China's total antibiotic use across all healthcare settings has increased significantly. The consumption of antibiotics in PHCs exceeded 50%, notably in the central regions (59%-68%). According to the Annual Pharmaceutical Production Statistics Report from the Ministry of Health, Labour, and Welfare ("MHLW") of Japan, the Japanese industry for both over the counter and prescription reached a value of US$109 billion in 2020. The market is predicted to expand in this region due to rising antibiotic usage and advancements in the pharmaceutical sector.
The China market dominated the Asia Pacific Penicillin Drug Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1.1 billion by 2030. The Japan market is anticipated to grow at a CAGR of 3.5% during (2023-2030). Additionally, The India market would register a CAGR of 4.8% during (2023-2030).
Based on Source, the market is segmented into Semisynthetic Penicillin and Natural Penicillin. Based on Spectrum of Activity, the market is segmented into Broad spectrum, Extended spectrum and Narrow spectrum. Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on Route of Administration, the market is segmented into Parenteral and Oral. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Pfizer, Inc., Novartis AG, Lupin Limited, Abbott Laboratories, Cipla Limited, Takeda Pharmaceutical Company Limited, Alkem Laboratories Ltd., Teva Pharmaceuticals Industries Ltd., Sun Pharmaceutical Industries Ltd.
Scope of the Study
By Source
- Semisynthetic Penicillin
- Natural Penicillin
By Spectrum of Activity
- Broad spectrum
- Extended spectrum
- Narrow spectrum
By Distribution Channel
- Drug Stores & Retail Pharmacies
- Hospital Pharmacies
- Online Providers
By Route of Administration
- Parenteral
- Oral
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- GlaxoSmithKline PLC (GSK)
- Pfizer, Inc.
- Novartis AG
- Lupin Limited
- Abbott Laboratories
- Cipla Limited
- Takeda Pharmaceutical Company Limited
- Alkem Laboratories Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Competition Analysis - Global
Chapter 5. Asia Pacific Penicillin Drug Market by Source
Chapter 6. Asia Pacific Penicillin Drug Market by Spectrum of Activity
Chapter 7. Asia Pacific Penicillin Drug Market by Distribution Channel
Chapter 8. Asia Pacific Penicillin Drug Market by Route of Administration
Chapter 9. Asia Pacific Penicillin Drug Market by Country
Chapter 10. Company Profiles
Companies Mentioned
- GlaxoSmithKline PLC (GSK)
- Pfizer, Inc.
- Novartis AG
- Lupin Limited
- Abbott Laboratories
- Cipla Limited
- Takeda Pharmaceutical Company Limited
- Alkem Laboratories Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
Methodology
LOADING...
